The advent of targeted therapy and global concerted efforts culminated in the introduction of targeted therapies, such as bevacizumab, a humanized antibody against the vascular endothelial growth factor A (VEGF-A), thus inhibiting angiogenesis and limiting tumor growth (Ferrara and Adamis, 2016, Garcia et al., 2020). The gene discussed is VEGFA; the disease is neoplasm.